Drug intelligence / Profile preview

ANS-TGF-β2

Development stage: Preclinical
Lead developer: Nestlé Health Science
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

ANS-TGF-β2 is an exclusive polymeric diet enriched with transforming growth factor-beta 2. It has been investigated for its use in remission induction and maintenance in pediatric Crohn's disease, and for decreasing postoperative complications after surgery for complicated ileocolonic Crohn's disease. The transforming growth factor-beta 2 component is a cytokine known for its immunomodulatory and anti-inflammatory properties.

Targets

TGFBR2 (TGF-β receptor type 2)TGFBR3 (TGF-β receptor type III)αVβ6 (Integrin αVβ6)TGFBR1

Beyond the preview

Go deeper on ANS-TGF-β2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANS-TGF-β2.

Explore the full profile